In our search for cell surface markers expressed on hematopoietic stem cells and/or very early progenitor cells we found that the Joro 177 monoclonal antibody (MoAb) bound to most hematopoietic cells in day 8/8.5 yolk sac, day 12 fetal liver, and day 13 fetal thymocytes; it stained hematopoietic stem cells and less immature lymphoid, myeloid, and erythroid-lineage cells, but not most thymocytes and splenic lymphocytes in adult mice. Joro 177 MoAb stimulated tyrosine phosphorylation of an -125-kD protein and induced homotypic aggregation of lymphoid progenitor cells. Importantly, Joro 177 MoAb inhibited cell survivallgrowth and URING MOUSE development, primitive hematolym-D phopoiesis occurs in distinct tissues/organs as the embryo develops. These include the yolk sac, which appears at day 7 of gestation; the liver primordium, which appears at day 8 or 9; the thymic anlage, which appears at day 9 or 10; and the spleen and bone marrow (BM), which appear at day 15 or 16. The heart starts beating at day 9, at which point blood circulation commences in the embryo. Definitive hematolymphopoiesis occurs mainly in the BM throughout the life time of the mouse.' Hematolymphopoiesis is a dynamic process marked by the stepwise loss of both selfrenewal and multifunctional potential as the pluripotent hematopoietic stem cell (PHSC) gives rise to progenitors for the different mature blood cell types. PHSC are unique in that they give rise both to new stem cells (self-renewal) and to all blood cell types. The self-renewal potential of PHSC is extensive as manifested in its ability to repopulate the hematopoietic system for long time (>5 to 6 months). Mouse BM and fetal liver (FL) cells with properties of PHSC express Sca-1 surface marker and c-Kit receptor and lack most lineage-restricted surface markers (Lin-) (eg, B-220 for Blymphocyte, Joro 75 for T-lymphocyte, Mac-1 for myeloid, TER119 for erythroid, 8C5 for granulocyte blood cell lineages).2-5 In humans, putative PHSC are included in the CD34' 33-DR-and CD34+33-DR+ marrow populations."'
The publication costs of this article were defrayed in part by page churge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 interactions with other cells from particular microenvironments, the growth factors that support cell division without differentiation of these cells, and the cellular and molecular events responsible for the choice between self-renewal and differentiation are still poorly understood. PHSC must express sets of genes whose products, acting in the nucleus, cytoplasm, or the cell membrane, participate in these processes. The molecules expressed on the cell membrane of PHSC are likely to play key roles, interacting with other cells (eg, stromal cells) and transmitting signals to and receiving them from a given microenvironment. Actually, these most probably dictate whether a PHSC will self-renew, differentiate, or even die.
We have previously generated the Joro series of rat monoclonal antibodies (MoAbs) using a mouse Pro-T cell clone as immunogen. The MoAbs were grouped according to their binding pattern to FL mononuclear cells, adult thymocytes, BM mononuclear cells, Pro-T cells, Pro-B cells, Pre-B cells, and a macrophage cell line.' This report describes detailed studies with one MoAb from group 7 called Joro 177.
MATERIALS AND METHODS

Animals
C57BL/6 and C3H severe combined immunodeficient (SCID) mice are bred and maintained in the animal barrier facility at our department. Male or female normal C57BL/6 (3 to I O weeks old) and female SCID mice (8 to 12 weeks old) that had no detectable Ig in their serum were used. C57BL/6 mouse embryos were obtained from timed matings; the day of detection of a vaginal plug was designated day 0.
6, I~I L -~, '~. '~
Cos-1 cells transfected with cDNA coding for Steel factor''; B9 transfected cells producing IL-I 1 were provided by R.G. Hawley (University of Toronto, Toronto, Ontario, Canada). Erythropoietin was purchased from B&D Systems (Minneapolis, MN). J558/L/FLT3-Ligand/2 transfectant cells producing recombinant mouse FLT3-ligand were developed by subcloning FLT3-ligand-mouse cDNA into the EcoRI-Xho I site of the pCDNA3 mammalian expression vector (Xie X, Li T, Palacios R, unpublished results, May 1994).
Antibodies
Biotin-, phycoerythrin (PE)-, or fluorescein isothiocyanate (FITC)-conjugated antibodies against Thy 1, LyT2 (CD8). L3T4 (CD4), CD3 (Hybridoma 145-2c1 l), B-220 (hybridoma 6B2), major histocompatibility complex (MHC) class I of the H-2b haplotype (hybridoma AF6-88.5), MHC class I of the H-2k haplotype (hybridoma AF3-12.1), Mac-1 (hybridoma M1/70), TER119, 8C5, T-cell receptor (TCR) ap (hybridoma H57-597), TCR yfJ (hybridoma GL3), a 4 integrin (PS/2), a 5 integrin (5H10), ICAM-I (YN1/1.7), ICAM-2 (MIC2), and Sca-1 were purchased from Pharmingen (San Diego, CA). FITC-and PE-conjugated F4/80 antibody was from SEROTEC (Kidlington, Oxford, UK). FITC-conjugated antimouse IgM, K light chain, and IgG and PE-streptavidin were from Southern Biotechnology Associates (Birmingham, AL). FITC-streptavidin was from Vector Laboratories (Burlingame, CA). Unconjugated and FITC-conjugated antirat IgG, purified mouse Ig, and rat Ig were from Jackson Immunoresearch Labs (West Grove, PA). Joro 75 and Joro 177' were prepared in our laboratory. Antibody against CD44 (KM703) was a gift from P.W. Kincade (Oklahoma Medical Research Foundation, Oklahoma City) and LFA-1 (H155-78) was a gift from M. Pierres (Centre d'Immunologie, Marseille, France). Antibodies against B l (9EG7) and B7 (FIB30.1) integrins were provided by D. Vestweber (MPI, Freiburg, Germany) and by E. Butcher (Stanford University, Stanford, CA), respectively. Antiserum against FAK and antiphoshotyrosine antibody (4G10) were from Upstate Biotechnology Incorporated (Lake Placid, NY). MoAbs were purified using the Monotrap II system from Pharmacia (Uppsala, Sweden) and conjugated to biotin as described before.'
Preparation of Mononuclear Cells
Mononuclear cells free of erythrocytes were prepared from spleen, thymus, BM of adult mice, and FL and fetal thymus as described before.' Yolk sac mononuclear cells from day 8/8.5 embryos were obtained as described.'' The cells were washed and resuspended in the required buffers (see below) or in culture medium (Iscove's modified Dulbecco medium supplemented with 5% to 7.5% heat-
moVL], and gentamycin [50 pg/mL]).
Isolation of Lin-and Joro I77+ Lin-Mononuclear Cells
BM mononuclear cells from 3 to 6-week-old mice and day 12 or 13 FL mononuclear cells were first depleted of Ig', Joro 75', B-220', F4/80+, 8C5', CD3' (in BM samples), and TER119' cells using magnetic beads coupled with sheep-antirat Ig (Dynabeads, Dynal, New York, NY) by incubating the cells with saturating concentrations of the antibodies at 4°C for 30 minutes; the cells were washed and incubated with beads coupled with sheep-antirat Ig (cross-reacts with mouse Ig) (beads-to-cell ratio of 30 to 1) at 4°C for 20 minutes. The magnetic-particle-bound cells were removed by applying a magnetic force; the magnetic-particle-free cells were collected and reexposed to the magnetic force for 5 to 10 minutes to further remove the particle-bound cells. The magnetic-particlefree cells were collected, spun, counted, and resuspended in culture medium; they are referred to as Lin-hematopoietic cells. Joro 177' Sca-1 + Lin-cells from day 12 FL were purified by further incubating FL Lin-cells obtained as described above, with appropriate dilutions of PE-or biotin-conjugated antibodies against F4/80, B-220, TERll9, 8C5, Joro 75, CD4, and FITC Sca-1 at 4°C for 30 minutes. The cells were washed and exposed to PE-streptavidin at 4°C for 20 minutes. After this, the cells were washed two times and resuspended in cell sorter buffer (phosphate-buffered saline [PBS] + 5% FCS + gentamycin), and the viable cells that were Sca-1' and negative for all the other markers (Lin-) were purified by cell sorter using an ELITE sorter Instrument (Coulter, Hialeah, FL) essentially as described before.Ib A proportion of the cell-sorter purified cells were used for staining with biotin-conjugated Joro 177 and allophycocyanin (APC)-streptavidin followed by fluorescence-activated cell sorter (FACS) analysis. This analysis showed that greater than 99% of the cells were Sca-1' Lin-and 100% Joro 177'; they are referred to as Joro 177+ Lin-cells.
Functional Assays
Lin-cells (10' cells/well) were cultured on monolayers of irradiated (2 to 3 Cy) ET cortical thymic epithelial cells on six-well Costar plates (Pleasanton, CA) in the presence of IL-7 (500 U/mL), Steel factor (100 U/mL), and FLT3-ligand (200 U/mL) in a final volume of 2 mL of culture medium per well at 37°C for 8 to 10 days. Cultures were performed in the presence or absence of purified (from 1 to 20 pg/mL) Joro 177 or Joro 75 MoAbs. The cells were procured, washed, and used for FACS analy~is.'~.'~ Lin-cells (IO' cells/mL) were cultured on monolayers of irradiated (2 to 3 Gy) FLS4.1 stromal cells on six-well Costar plates in the presence of IL-7 (500 U/mL), Steel factor (100 U/mL), and IL-11 (100 UlmL) in a final volume of 2 mL of culture medium at 37°C for 8 to 10 days. Cultures were performed in the presence or absence of purified (from 1 to 20 pg/ mL) Joro 177 or Joro 75 MoAbs. The cells were obtained and washed and used for FACS analysis.","
Myeloiderythroidmegakuryocyte-cell dzferentiation. Lin-cells (10' cells/well) were cultured in six-well Costar plates containing GM-CSF (200 U/mL), Steel factor (100 U/mL), erythropoietin (2 U/mL), IL-3 (2 U/mL), and IL-11 (100 U/mL) in a final volume of 2 mL of culture medium per well at 37°C for 8 to 10 days. Cultures were performed in the presence or absence of purified (from 1 to 20 pg/mL) Joro 177 or Joro 75 MoAbs. The cells were obtained, washed, and used for FACS analysis.'', '6 In vivo hematopoietic reconstitution. For repopulation of sublethally irradiated (300 rads of gamma rays) C3H-SCID-SCID mice, the cell sorter purified Joro 177+ Lin-FL mononuclear cells from day 12 C57BL16 embryos (5 x lo3 cells/0.4 mL of PBS) or PBS alone were injected intravenously (IV) into the recipient animal 2 to 4 hours after irradiation. All mice were housed in sterile isolators with sterile food in a laminar flood hood. Hematopoietic reconstitution in BM and spleen of SCID mice was assessed by single-and two-color FACS analysis (see below) 5 to 6 months later.
FTH5 pro-T cells (1.5 to 2 X 10') suspended in 100 pL of culture medium supplemented with IL-2 (final concentration 10 U/mL) were placed in 96-well flatbottomed microplates in the presence or absence of Joro 177 MoAb, PS12 a4-integrin-specific MoAb, or CD44-specific MoAb KM703 (final dilution 1:3 of hybridoma culture supernatants) at 37°C for 2 to 3 hours. Cell aggregation was determined by direct visualization of the cultures with an inverted microscope. In the experiments in which the various drugs or the cell-adhesion-specific MoAbs indicated in the results section were tested for their inhibitory effect on cell aggregation, the FTH5 cells were preincubated with the drugs (at 37°C for 1 hour) or with the blocking antibodies (at 4°C for 30 minutes) before use in the cell aggregation assay.
T-cell differentiation.
B-cell differentiation.
Homotypic cell aggregation assay.
For personal use only. on October 22, 2017. by guest www.bloodjournal.org From Western blot analysis for detection of tyrosine phosphorylated proteins. FTH5 cells were procured, and washed twice in PBS, and 5 X 10' cells were preincubated at 37°C for 30 minutes before addition of Joro 177 MoAb or MW2 control antibody. At various intervals, the cells were pelleted by centrifugation at 2,000~ for 20 seconds and lysed in 1 mL of lysis buffer (1% NP-40, 50 mmol/L Tris-HCL pH 7.4, 150 mmoVL NaCL, 2 mmol/J+ phenylmethylsulfonyl fluoride [PMSF], 1 mmoVL Na2V04, 2 mmoVL NaF, and 5 mmol/L EDTA) at 4°C for 60 minutes. Insoluble material was pelleted by centrifugation at 14,OOOg at 4°C for 15 minutes. The supernatant was transferred to a fresh tube containing 5 pg phosphotyrosine-specific antibody 4G10 and Protein A-Sepharose (Pharmacia) and precipitation was allowed to proceed at 4°C overnight. The Sepharose beads were washed three times in lysis buffer, and boiled in Laemmli sample buffer, and proteins were separated under reducing conditions by 7.5% sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis. After transfer into nitrocellulose filters, the proteins were Western blotted with antibody 4G10 (0.25 pg/ mL). Detection was with horseradish peroxidase-coupled secondary antibodies and the enhanced chemiluminescence system (Amersham, Arlington Heights, IL).
Apoptosis was assessed essentially as described before.34 Lin-cells (0.5 to 1 X 10' cultured in medium containing GM-CSF, IL-11, Steel factor) were treated with Joro 177 MoAb or Joro 75 MoAb (final concentration 10 pg/mL) in the presence or absence of F(ab)2-antirat IgG (final concentration 5 pg/mL) at 37°C for 24 hours. The cells were procured, and washed, and DNA was isolated and fractionated by electrophoresis on I .5% agarose gels. DNA was visualized by staining with ethidium bromide and photographed under UV light using a transilluminator.
cDNA library construction and expression cloning. Poly(A)+ RNA isolated from the FTH5 cell line was used to generate a cDNA library constructed in the pCDNAI mammalian expression vector (InVitrogen, San Diego, CA). To isolate cDNA encoding the protein recognized by Joro 177 MoAb, we followed the cloning expression system developed by Seed and Aruffo" with some modifications. was performed by primer walking in an AB1 automatic DNA sequencer (Applied Biosystems, Foster City, CA). DNA and protein sequence analysis and comparisons were made using the GCG and MacDNASIS 2 software packages. Searches in the GeneBank, Swissprot, and OWL databases were made using the BLAST programs.
FACS was performed as described in detail previously.'.",'' All stainings were performed with cell samples that were preincubated with heat-inactivated hamster serum (1 0% to 15%) and purified rat IgG (250 pg/mL) to prevent nonspecific Fcreceptor binding of labeled antibodies. Single-and two-color FACS analysis were performed using Coulter Profile and ELITE V instruments. BM, spleen, and thymocytes from normal mice were used as positive controls as required and to set up electronically green and red compensations. Cells exposed to second-step reagents were used as negative controls. from analysis by forward and side scatter gating. Data collected from IO" cells were analyzed and displayed in the form of fluorescence histograms (single color) or dot plots (two color).
RESULTS
Immunofluorescence staining of cell lines representing different hematopoietic cell lineages and FACS analysis showed that Pro-T cell clones (C4-77, FTHS), the thymic lymphoma BW5 147, activated E-%-dependent mature cytolytic CFLl T-cells, B-celYmyelocytic progenitors (LyD9), the Pro-B cell line CB/Bm7, the Re-B cell line 18.81, the immature B-cell lymphoma WEHI 279, the myeloid progenitor cell line Mye5, and the macrophage cell line P388D1 were all positive for the Joro 177 surface antigen.'
Ident$cation of Joro 177' Cells in Hematopoietic Tissues of Adult Mice and Embryos
We found that in the BM 70% to 80% of mononuclear cells included in the "lymphoid" gate (defined by forward and side scatters) and 42% to 45% mononuclear cells included in the "myeloid" gate were Joro 177'. In the adult thymus, only less than 2% of the small thymocytes (which comprise -95% of the thymocytes), but 85% to 100% of the large thymocytes (which usually represent 4% of the thymocytes and includes most of the CD4-CD8-CD3-thymocyte precursors) bound Joro 177. The spleen contained 5% to 12% Joro 177' cells, but after activation with the polyclonal T-cell mitogen Concanavalin A or with the polyclonal B-cell mitogen lipopolysaccharide (LPS) the percentage of Joro 177' increased up to 45% to 73% (Table 1 and data not shown).
Two-color FACS analysis using lineage-characteristic surface markers and Joro 177 MoAb were performed to further determine the expression of Joro 177 among the different blood cell lineages. About 30% to 39% of the B-220+ Blymphocyte lineage cells but less than 1% of the IgM+ mature B lymphocytes in the BM were Joro 177'. Between 19% and 24% of the marrow granulocytes identified with For personal use only. on October 22, 2017. by guest www.bloodjournal.org From FACS analysis of mononuclear cells included in the "lymphoid" or the "myeloid" gates (determined by forward and side scatters) was performed to determine the percentage of Joro 177' cells coexpressing the lineage-restricted surface markers indicated. The numbers are the range of double-positive cells detected in three separate experiments.
the 8C5 surface marker and 15% to 17.6% of the myeloid cells identified with the Mac-1 surface marker in the BM were also Joro 177+. About 4.6% to 6.4% of marrow cells coexpressed the erythroid-lineage marker TERll9 and Joro 177, and less than 1% marrow cells stained with Joro 177 and either Thy 1 expressed on PHSC and T lymphocytes or the Joro 75 surface marker for T-cell progenitors (Table 2) .
Similar FACS analysis showed that 73% to 89% of hematopoietic cells in the yolk sac at day W8.5 of gestation (before blood circulation has started in the embryo) and essentially 100% of mononuclear cells from FL at day 12 of gestation were strongly positive for Joro 177 ( Most adult thymocytes and splenic mature T lymphocytes and B lymphocytes carry very low or no detectable Joro 177 antigen on the cell membrane (Tables 1 and 2 ). Interestingly, a significant proportion of the splenic mature T and B lymphocytes become Joro 177+ after their activation in vitro by polyclonal mitogens. The latter results, together with the finding that most large thymocytes (known to contain actively dividing cells) and most proliferating cell lines including transformed lymphoma cells representing mature B lymphocytes and T lymphocytes, brightly stained with the Joro antibody: suggest that proliferating lymphoid cells express higher levels of Joro 177 than quiescent lymphocytes. Taken together, these results show that Joro 177 is expressed on hematopoietic stem cells, T-and B-cell precursors, and a subset of myeloid and erythroid-lineage cells. Most mature peripheral T and B lymphocytes are Joro 177-but become positive after their activation by mitogens.
Joro 177 Is Expressed on Lin-FL Pluripotent Hematopoietic Stem Cells
To test directly whether Joro 177 was expressed on pluripotent hematopoietic stem cells (PHSC), we purified Joro 177+ Sca-1' Lin-(B-220, F4/80, 8C5, Joro 75, TERl19-) cells from fetal livers of day 12 C57BLJ6 mouse embryos using FACS (see Materials and Methods for details). The purified Joro 177+ Lin-FL mononuclear cells were then tested for their ability to give rise to lymphoid, myeloid, and erythroid-hematopoietic cell lineages and to reconstitute the hematopoietic system for a long time (>5 months), the two characteristic properties of PHSC. To this end, we injected IV purified Joro 177+ Lin-FL hematopoietic precursor cells of C57BL/6 origin (H-2b) into sublethally irradiated immunodeficient C3H SCID (H-2k) mice. The progeny of donor origin (C57BU6, H-2b) were distinguished from cells of host origin (C3H, H-2k) by an H-2b-specific MoAb known to react with cells expressing class I MHC of the H-2b but not with cells bearing class I MHC of the H-2k haplot y p e~,~~.~' along with appropriate hematopoietic lineage-specific surface markers and two-color FACS analysis.
The results are summarized in Table 3 . SCID mice that received Joro 177+ Lin-FL cells 5 months before analysis, but not the control mice (which received no cells), contained significant numbers of donor-derived B-lymphocyte precursors (H-2b+ B-220+), T-lymphocyte precursors (H-2b+ Joro 759, myeloid-lineage cells (H-2b+ Mac-1' ) and erythroidlineage cells (H-2b+ TER119') in the BM and mature T lymphocytes (H-2' CD3+) and mature B lymphocytes (H2bf IgM+) in the spleen. These results strongly argue that Joro 177 is expressed by FL hematopoietic cells with properties of PHSC.
Joro 177 Induces Homotypic Aggregation of Lymphocyte Progenitor Clones
By serendipity, it was found that Joro 177 MoAb induced homotypic aggregation of nontransformed, growth-factordependent lymphoid progenitor lines such as the Pro-T cell clone FTH5.I' FTH5 cells grow as a single-cell suspension in culture medium supplemented with their required exogenous growth factors IL-2 or IL-3. The addition of Joro 177 MoAb to these cultures increased the adhesiveness of FTH5 cells so that they aggregated (Fig 1) . Aggregation was at least as extensive as that induced by an a 4 integrin specific antibody. The latter integrin was previously found to participate in aggregation of peripheral blood mononuclear cells.lg Maxi- (Fig 1) . Secondly, as Table   4 shows, homotypic aggregation was not observed if the treatment was performed at 4"C, and it was abolished by Table  5 ) . The other feature is that unlike previously described homotypic aggregations of hematopoietic cells induced by sev- For personal use only. on October 22, 2017. by guest www.bloodjournal.org From eral means, the aggregation induced by Joro 177 MoAb required protein synthesis (Table 4) .
Next, we attempted to block the cell aggregation induced by Joro 177 MoAb with antibodies against cell adhesion molecules (CAMS). None of the antibodies tested against CD44 (KM703), a 4 integrin (PS/2), a5 integrin (5H10), a6 integrin (EA-l), LFA-1 (H155-78), ICAM-1 (YN1/1.7), and ICAM-2 (MIC2) blocked the Joro 177 MoAb-induced homotypic aggregation of FTH5 cells. Table 4) showed that inhibitors of protein tyrosine kinases (genistein, herbimycin B) or of protein tyrosine phosphatases (ZnCl,, sodium ortho vanadate) inhibited Joro 177 MoAb-induced homotypic aggregation, suggesting the involvement of these enzymes in this process. In contrast, staurosporine, a specific inhibitor of protein kinase C (PKC), did not affect homotypic aggregation. An inhibitor of PKC, PKG, and PKA (H7), a specific inhibitor of PKA (H8), and an inhibitor of Na+/ Ca2+ exchange (bepridil) significantly decreased homotypic aggregation of lTH5 cells elicited by Joro 177 MoAb.
Subsequent experiments (also compiled in
Joro 177 MoAb Stimulates Tyrosine Phosphorylation of a 125-kD Protein in FTHS Pro-T Cells
Since protein tyrosine kinase-and phosphatase-specific inhibitors abolished Joro 177 MoAb-induced homotypic aggregation of lTH5 cells, we searched for tyrosine phosphorylation of proteins in these cells after exposure to Joro 177 MoAb. These experiments were performed in the absence of cytokines to exclude the possibility that any tyrosine phosphorylated protein detected could be caused by the cytokine rather than by Joro 177 MoAb stimulation. Western blot analysis of lysates from lTH5 cells treated with Joro 177 MoAb or a control MW2 antibody, using a phosphotyrosinespecific antibody, showed increased tyrosine phosphorylation of a 125-kD protein in FTH5 cells exposed to Joro 177
MoAb but not in lysates of cells treated with the control antibody. Interestingly, the increased phosphorylation was apparent 2 to 5 minutes after Joro 177 MoAb stimulation; phosphorylation levels returned to basal levels 20 to 60 minutes later (Fig 2A and B) . These results and those demonstrating the induction of homotypic aggregation on Joro 177 MoAb binding to FTH5 cells lead us to conclude that the cell-membrane protein recognized by the Joro 177 MoAb can transduce signals into the cell.
Joro I77 MoAb Inhibits Cell SurvivaUGrowth and DifSerentiation of Lin-Hematopoietic Precursors Along the Lymphoid, Myeloid, and Erythroid Cell Pathways
We next investigated whether the Joro 177 molecule participates during development of very early Lin-hematopoietic precursors into the lymphoid, myeloid, or erythroid cell lineages. To this end, Joro 177 MoAb or Joro 75 MoAb (used as an isotype-matched control antibody) were added to cultures in which purified Lin-hematopoietic precursor cells isolated from either day 13 or 14 FL or the BM of young adult mice were induced to differentiate along the Tlymphocyte, the B-lymphocyte, or the myeloiderythroid cell pathways using appropriate in vitro induction assay systems described in detail Table 6 illustrates with one example the results obtained in these experiments. We found that the Joro 177 MoAb significantly reduced the number of viable cells recovered at the end of all three different types of culture. The absolute number of CD4+ TCR-precursors and CD4+ TCR+ T cells and CD4-TCR+ produced in the cultures supporting T-cell differentiation, B-220+ IgM-Bcell precursors and B-220+ IgM+ mature B cells generated in the cultures promoting B-lymphocyte differentiation, and Mac-l+, 8C5+ myeloid cells and TER119+ erythroid cells produced in the assay cultures supporting differentiation along these hematopoietic lineages, was significantly decreased in the cultures exposed to the Joro 177 MoAb. In contrast, the isotype-matched control antibody Joro 75 did Western blot analysis.
the number of cells recovered at the end of the adult mice. Also, the same phenomenon was found in similar cultures nor the absolute number of T-lymphoid, Bcultures in which we used long-term cultured multipotent lymphoid, and myeloid and erythroid lineage cells generated precursor lines instead of freshly isolated Lin-FL or BM by Lin-FL precursor cells ( Table 6) . Similar results were cells. In some experiments, Joro 177 MoAb blocked comobtained using Lin-BM precursor cells purified from young pletely the generation of mature CD4' TCR' T cells or IgM' (Fig 3, lane B) ; this sign of apoptosis" was more apparent if cross-linking of Joro 177 MoAb bound to Lin-cells was promoted by F(ab)2 antirat IgG specific antibody (Fig 3, lane C) . In contrast. Lin-cells exposed to control Joro 75 MoAb and F(ab)? antirat IgG antibody showed no signs of DNA fragmentation (Fig 3,  lane A) . Thus, Joro 177 MoAb can initiate programmed cell death in hematopoietic progenitors.
Molecrrl~ir Cloning and E.~pre~.vioti of cDNA Encoding the Protein Recognized bv Joro I77 MoAb
To characterize further the cell membrane molecule recognized by Joro 177 MoAb, cDNA encoding this protein was isolated using a transient expression assay in Cos-I cells."' After three consecutive rounds of selection of transfectant Cos-I cells, one clone, Joro 177-87, was obtained that, upon transfection into Cos cells, conferred expression of detectable Joro 177 antigen on the cell membrane (Fig 4) . The Joro 177-87 cDNA was -I .8 kb in length and included a poly (A)' tract. This clone contained a single open reading frame of 533 codons that extended from an Met initiation codon at nucleotides I 10 through 112 to a stop codon at 1706 through 1708. The Met initiation codon at nucleotides 1 10-1 12 was preceded by an inframe UAG stop codon at nucleotides 56-58 and it was embedded in a context favorable for translation."' The start of the poly (A) addition signal was 17 nucleotides from the poly (A) tail and had the sequence AAUAAA.
The protein deduced from the clone Joro 177-87 nucleotide sequence had a predicted Mr 58817 and a predicted isoelectric point of 5.55. The deduced amino acid sequence of Joro 177-87 cDNA (Fig SA) 370, 445-448, and 504-508). Neither potential tyrosine lunase phosphorylation nor potential tyrosine kinase catalytic motifs could be found in the Joro 177-87-deduced amino acid sequence as determined by the SOPM program.*' We also notice two cysteine residues, at positions 109 and 33 1, that may serve for covalent heterodimer formation between this and other proteins. The Kyte and Doolittle blot analysis of the deduced amino acid sequence for the presence of membrane-associated segments showed the presence of a typical transmembrane-spanning region between amino acids 76 and 98; as found in other membrane proteins, this region is preceded and followed by basic residues (Fig 5B) . The other additional hydrophobic regions do not fit the requirements of typical transmembrane segments because they are interrupted by charged residues and lack the basic amino acids in the flanking sequences. The observations that the protein exhibits a strongly hydrophilic NH,-terminal region and lacks the signal peptide found on most transmembrane protein precursors, together with the presence of potential N-glycosylation sites COOH-terminal to the putative membrane spanning region, indicate that the Joro 177-87 cDNA codes for a type I1 transmembrane glycoprotein.
Searches in the Genbank, Swissprot, and OWL databases using the BLASTn, BLASTx, and GAP programs showed that the Joro 177-87 cDNA has 77.5% nucleotide sequence identity and 76.4% and 86.4% amino acid sequence identity and similarity, respectively, to the heavy chain of human CD98 (22-24) (Fig 5A) and 100% nucleotide sequence identity to a cDNA coding for the mouse CD98 heavy-chain gene which was isolated by screening cDNA libraries using human CD98-specific probes. Our results indicate that the Joro 177 antigen may be among the first cell surface molecules expressed by the developing blood cells at sites of primitive hematopoiesis (8/ 8.5 day yolk sac and 12 day FL). Furthermore, our studies show that Joro 177 MoAb is expressed on pluripotent hematopoietic stem cells, T-and B-lymphocyte precursors, a subset of myeloid and erythroid-lineage cells, most day 13 or 14 fetal thymocytes, and the subset of large double-negative cells in the adult thymus. However, Joro 177 MoAb does not bind to most double-positive (CD4+ 8+) and single-positive (CD4'8-or CD4-8+) thymocytes nor to most mature T lymphocytes and B lymphocytes in the spleen of adult mice. Mature lymphocytes could be induced to express Joro 177 antigen on the cell surface after their activation in vitro; this finding points out that Joro 177 may also serve as a marker for activated peripheral lymphocytes. Northern blot studies have shown that CD98 heavy-chain RNA transcripts are synthesized in the brain, kidney, lung, and suggesting that CD98 also could be expressed by some nonhematopoietic cells.
In experiments aimed to uncover functions of the molecule recognized by the Joro 177 MoAb in the hematopoietic system, we obtained evidence that CD98 can transduce signals into the cell that was manifested in both the tyrosine phosphorylation of an -125-kD protein and the induction of homotypic aggregation in a Pro-T cell progenitor line. Because the CD98 heavy-chain protein lacks protein tyrosine kinase catalytic sites, we surmise that Joro 177 MoAb binding to CD98 on FHTS progenitor cells stimulates a tyrosine kinase that in turn phosphorylates the -125-kD target protein, the nature of this phosphotyrosine protein remains to be elucidated. The tyrosine phosphorylation levels of the -125-kD protein returned to basal levels 20 to 60 minutes after Joro 177 MoAb stimulation, implying that this target protein might be subject to regulation by a tyrosine phosphatase.
The homotypic aggregation triggered by Joro 177 MoAb binding to CD98 required divalent cations, protein synthesis, and microfilament assembly and was dependent on metabolic energy and temperature. Our results using available blocking antibodies against mouse a4B1, uSB1, a6B1, LFA-1/ ICAM -1hCAM-2 integrins indicate that either these molecules do not participate in the homotypic aggregation elicited by the Joro 177 MoAb or that the antibodies used do not interfere with epitopes critical for homotypic aggregation in this system. Other cell adhesion molecules (eg, cadherins) could be involved in this process. It seems likely that the stimulation of tyrosine phosphorylation of the 125-kD protein and the induction of homotypic aggregation (which was abolished by both tyrosine kinase and tyrosine phosphatasespecific inhibitors) following Joro 177 MoAb binding to CD98 on ITHS Pro-T cells are related.
We also found that Joro 177 MoAb specifically inhibited growth/cell survival of Lin-early hematopoietic precursor cells induced to develop along the lymphocyte, myeloid, and erythrocyte pathways. Joro 177 MoAb induced apoptosis of the developing hematopoietic cells in the cultures. Several potential mechanisms could account for these results.
One possibility is that CD98 controls the uptake or exchange of essential nutrients (amino acids, divalent cations) necessary for cell survival/growth of cells. Joro 177 MoAb would block this function by binding to CD98. Support for this mechanism comes from previous studies reporting that the human CD98 heavy chain stimulated the uptake of neutral and dibasic amino acids in Xenopus o o~y t e s ,~~~~~ and that human CD98-specific antibodies inhibited sodium-dependent calcium exchange in sarcolemmal vesicles.3o However, two findings argue strongly against this possibility. mRNA for the CD98 heavy chain gene is expressed at very low levels in heart and skeletal muscle,25 two tissues very active in sodium-calcium exchange, and, in contrast to other previously described ion channels that contain multiple membrane-spanning domain^,^' the CD98 heavy-chain protein contains a single transmembrane region. Also, the putative role of CD98 as controller of ion channels or as an actual ion channel exchanger cannot satisfactorily explain the finding that the human CD98 heavy-chain-specific antibody 4F2 inhibits lectin-induced proliferation of peripheral blood lymphocytes but has no effect on other ion-dependent cell responses such as antibody-dependent cellular cytotoxicity or killing by alloantigen-specific cytotoxic T cells.26 Furthermore, although this mechanism could explain the blockage of hematopoietic growthldifferentiation of Lin-precursor cells caused by Joro 177 MoAb shown here, it does not readily explain the induction of both tyrosine phosphorylation and homotypic aggregation elicited by binding of Joro 177 MoAb to CD98 in hematopoietic progenitor cells.
Another mechanism, the one most attractive to us, postulates that CD98 and its putative ligand constitute a receptor/ ligand pair normally involved in controlling cell survival/ apoptosis. Thus, the CD98 receptornigand pair would control cell numbers and/or the extent of cell expansion of cells that are: (1) resting CD98-that become CD98+ after activation by antigens, cytokines (eg, resting T lymphocytes become highly CD98+ after their activation by mitogens or antigens), and (2) already CD98' cells present in different tissues in the developing embryo and tissues with continued cell reFor personal use only. on October 22, 2017. by guest www.bloodjournal.org From newal in the adult (eg, developing hematopoietic progenitors). The postulated role of CD98 in controlling cell survival/death is directly supported by the results showing that Joro 177 MoAb can induce programmed cell death in hematopoietic progenitors and by the data showing that this antibody significantly decreased the number of lymphoid, myeloid, and erythroid cells generated in culture by developing Lin-hematopoietic precursor cells. Moreover, also consistent with this view is the finding that ligation of CD98 on the cell membrane by Joro 177 MoAb elicited signal transduction events manifested by tyrosine phosphorylation of proteins and increased adhesiveness, resulting in homotypic aggregation of cells. This suggested function for CD98 also readily explains results by other research groups showing that CD98-specific antibodies inhibited the growth of human tumor cell lines," the proliferation of normal human lymphocytes after their activation by mitogens" and the reported existence of a subset of human natural killer cells that specifically recognizes and kills target cells bearing CD98. '5 
